rs386833497
Positions:
Variant summary
Our verdict is Likely pathogenic. Variant got 7 ACMG points: 7P and 0B. PVS1_StrongPM2PP5
The NM_000112.4(SLC26A2):c.1650delG(p.Ser551fs) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000694 in 1,614,042 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: 𝑓 0.000026 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000074 ( 0 hom. )
Consequence
SLC26A2
NM_000112.4 frameshift
NM_000112.4 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 0.997
Genes affected
SLC26A2 (HGNC:10994): (solute carrier family 26 member 2) The diastrophic dysplasia sulfate transporter is a transmembrane glycoprotein implicated in the pathogenesis of several human chondrodysplasias. It apparently is critical in cartilage for sulfation of proteoglycans and matrix organization. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_pathogenic. Variant got 7 ACMG points.
PVS1
Loss of function variant, product does not undergo nonsense mediated mRNA decay. Variant is located in the 3'-most exon, not predicted to undergo nonsense mediated mRNA decay. There are 4 pathogenic variants in the truncated region.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 5-149981242-AG-A is Pathogenic according to our data. Variant chr5-149981242-AG-A is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 56016.We mark this variant Likely_pathogenic, oryginal submissions are: {Uncertain_significance=1, Pathogenic=2, Likely_pathogenic=3}. Variant chr5-149981242-AG-A is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SLC26A2 | NM_000112.4 | c.1650delG | p.Ser551fs | frameshift_variant | 3/3 | ENST00000286298.5 | NP_000103.2 | |
SLC26A2 | XM_017009191.3 | c.1650delG | p.Ser551fs | frameshift_variant | 3/4 | XP_016864680.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SLC26A2 | ENST00000286298.5 | c.1650delG | p.Ser551fs | frameshift_variant | 3/3 | 1 | NM_000112.4 | ENSP00000286298.4 | ||
SLC26A2 | ENST00000503336.1 | c.372+2892delG | intron_variant | 3 | ENSP00000426053.1 |
Frequencies
GnomAD3 genomes AF: 0.0000263 AC: 4AN: 152206Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
4
AN:
152206
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00000797 AC: 2AN: 250808Hom.: 0 AF XY: 0.0000147 AC XY: 2AN XY: 135736
GnomAD3 exomes
AF:
AC:
2
AN:
250808
Hom.:
AF XY:
AC XY:
2
AN XY:
135736
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000739 AC: 108AN: 1461836Hom.: 0 Cov.: 34 AF XY: 0.0000715 AC XY: 52AN XY: 727216
GnomAD4 exome
AF:
AC:
108
AN:
1461836
Hom.:
Cov.:
34
AF XY:
AC XY:
52
AN XY:
727216
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000263 AC: 4AN: 152206Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74354
GnomAD4 genome
AF:
AC:
4
AN:
152206
Hom.:
Cov.:
32
AF XY:
AC XY:
0
AN XY:
74354
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:8Uncertain:1
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
Achondrogenesis, type IB Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 06, 2024 | - - |
Likely pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 28, 2020 | - - |
SLC26A2-related disorder Pathogenic:1Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Oct 01, 2016 | The SLC26A2 c.1650delG (p.Ser551ValfsTer34) variant, which is also reported as c.1677delG, results in a frameshift and is predicted to result in premature termination of the protein. The p.Ser551ValfsTer34 variant was reported in a single study in which it was found in one individual with diastrophic dysplasia, although zygosity information was not provided (Rossi et al. 2001). The p.Ser551ValfsTer34 variant was absent from 100 controls and is reported at a frequency of 0.00002 in the European (non-Finnish) population of the Exome Aggregation Consortium. This frequency is based on a single allele in a region of good sequence coverage, so the variant is presumed to be rare. Due to the potential impact of frameshift variants and the lack of clarifying evidence, the p.Ser551ValfsTer34 variant is classified as a variant of unknown significance but suspicious for pathogenicity for SLC26A2-related disorders. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. - |
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Aug 05, 2024 | The SLC26A2 c.1650delG variant is predicted to result in a frameshift and premature protein termination (p.Ser551Valfs*34). This variant along with a second variant in this gene has been reported in at least one individual with diastrophic dysplasia (Paganini et al. 2023. PubMed ID: 37454964). This variant is reported in 0.00088% of alleles in individuals of European (non-Finnish) descent in gnomAD. Frameshift variants in SLC26A2 are expected to be pathogenic. This variant is interpreted as pathogenic. - |
Multiple epiphyseal dysplasia type 4 Pathogenic:1
Likely pathogenic, criteria provided, single submitter | literature only | Counsyl | Jan 23, 2015 | - - |
Diastrophic dysplasia;C0265274:Achondrogenesis, type IB;C1847593:Multiple epiphyseal dysplasia type 4;C1850554:Atelosteogenesis type II Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 12, 2024 | This sequence change creates a premature translational stop signal (p.Ser551Valfs*34) in the SLC26A2 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 189 amino acid(s) of the SLC26A2 protein. This variant is present in population databases (rs386833497, gnomAD 0.002%). This premature translational stop signal has been observed in individual(s) with clinical features of SLC26A2-related conditions (PMID: 11241838). ClinVar contains an entry for this variant (Variation ID: 56016). This variant disrupts a region of the SLC26A2 protein in which other variant(s) (p.Glu703Glyfs*9) have been determined to be pathogenic (Invitae). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. - |
not provided Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Mar 18, 2021 | Frameshift variant predicted to result in protein truncation, as the last 189 amino acids are replaced with 33 different amino acids, and other loss-of-function variants have been reported downstream in the Human Gene Mutation Database (Stenson et al., 2014); Not observed at a significant frequency in large population cohorts (Lek et al., 2016); Identified in a patient with diastrophic dysplasia in the published literature (Rossi et al., 2001); This variant is associated with the following publications: (PMID: 11241838) - |
Sulfate transporter-related osteochondrodysplasia Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Dec 29, 2022 | Variant summary: SLC26A2 c.1650delG (p.Ser551ValfsX34) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been associated with Disatrophic Dysplasia in HGMD. The variant allele was found at a frequency of 8e-06 in 250808 control chromosomes. c.1650delG has been reported in the literature in individual(s) affected with Diastrophic Dysplasia (Rossi_2001). To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Five clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 and classified it as: Pathogenic (n=1), Likely Pathogenic (n=3) and VUS (n=1). Based on the evidence outlined above, the variant was classified as likely pathogenic. - |
Diastrophic dysplasia Pathogenic:1
Likely pathogenic, no assertion criteria provided | literature only | Juha Muilu Group; Institute for Molecular Medicine Finland (FIMM) | - | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at